Does Tumor FDG-PET-Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?

[1]  B. Faubert,et al.  Metabolic diversity in human non-small cell lung cancer , 2014, bioRxiv.

[2]  R. Deberardinis,et al.  Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. , 2018, Cell metabolism.

[3]  Jamey D. Young,et al.  Lactate Metabolism in Human Lung Tumors , 2017, Cell.

[4]  Francisco J. Sánchez-Rivera,et al.  Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.

[5]  M. Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Z. Xuan,et al.  The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition , 2017, Nature Communications.

[7]  Benjamin P. C. Chen,et al.  CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells , 2017, Nature.

[8]  A. Schulze,et al.  The multifaceted roles of fatty acid synthesis in cancer , 2016, Nature Reviews Cancer.

[9]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[10]  Abhishek K. Jha,et al.  Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. , 2016, Cell metabolism.

[11]  R. Deberardinis,et al.  Oxidative stress inhibits distant metastasis by human melanoma cells , 2015, Nature.

[12]  Zhaoyuan Fang,et al.  LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. , 2015, Cancer cell.

[13]  A. Lane,et al.  Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. , 2015, The Journal of clinical investigation.

[14]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[16]  H. Coller,et al.  The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. , 2010, Genes & development.

[17]  W. Travis,et al.  Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. , 2009, Archives of pathology & laboratory medicine.

[18]  T. Fan,et al.  Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM) , 2009, Molecular Cancer.

[19]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[20]  Tsutomu Araki,et al.  Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET , 2009, Annals of nuclear medicine.

[21]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[22]  J. Mortensen,et al.  Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. , 2001, The Lancet. Oncology.

[23]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.